Self-assembled peptide-polyoxometalate hybrid nanospheres: two in one enhances targeted inhibition of amyloid β-peptide aggregation associated with Alzheimer's disease
- PMID: 23650245
- DOI: 10.1002/smll.201202612
Self-assembled peptide-polyoxometalate hybrid nanospheres: two in one enhances targeted inhibition of amyloid β-peptide aggregation associated with Alzheimer's disease
Abstract
Amyloid fibril formation is a critical step in Alzheimer's disease (AD) pathogenesis. Inhibition of Aβ aggregation has shown promising against AD and has been used in clinic trials. Here, a novel strategy is reported for the self-assembly of polyoxometalate-peptide (POM@P) hybrid particles as bifunctional Aβ inhibitors. The two-in-one bifunctional POM@P nanoparticles show an enhanced inhibition effect on amyloid aggregation in mice cerebrospinal fluid. Incorporating a clinically used Aβ fibril-staining dye, congo red (CR), into the hybrid colloidal spheres, the nanoparticles can also act as an effective fluorescent probe to monitor the inhibition process of POM@P via CR fluorescence change in real time. It is believed that such flexible organic-inorganic hybrid systems may prompt the design of new multifunctional materials for AD treatment.
Keywords: alzheimer's disease; amyloids; nanoparticles; peptide inhibitors; polyoxometalates; self-assembly.
Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Similar articles
-
Gold-nanoparticle-based multifunctional amyloid-β inhibitor against Alzheimer's disease.Chemistry. 2015 Jan 7;21(2):829-35. doi: 10.1002/chem.201404562. Epub 2014 Nov 5. Chemistry. 2015. PMID: 25376633
-
Mo polyoxometalate nanoclusters capable of inhibiting the aggregation of Aβ-peptide associated with Alzheimer's disease.Nanoscale. 2014 Jun 21;6(12):6886-97. doi: 10.1039/c3nr05906e. Nanoscale. 2014. PMID: 24834443
-
Chiral Metallo-Supramolecular Complex Directed Enantioselective Self-Assembly of β-Sheet Breaker Peptide for Amyloid Inhibition.Small. 2015 Sep;11(36):4651-5. doi: 10.1002/smll.201501329. Epub 2015 Jul 1. Small. 2015. PMID: 26136296
-
Alzheimer's disease.Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Subcell Biochem. 2012. PMID: 23225010 Review.
-
Alzheimer's disease: β-amyloid plaque formation in human brain.Synapse. 2011 Dec;65(12):1289-97. doi: 10.1002/syn.20957. Synapse. 2011. PMID: 21633975 Review.
Cited by
-
Novel fabrication of Cu(II)-incorporated chiral d-penicillamine-chitosan nanocomposites enantio-selectively inhibit the induced amyloid β aggregation for Alzheimer's disease therapy.Heliyon. 2023 Dec 11;10(1):e23563. doi: 10.1016/j.heliyon.2023.e23563. eCollection 2024 Jan 15. Heliyon. 2023. PMID: 38223723 Free PMC article.
-
Advancements in the Application of Nanomedicine in Alzheimer's Disease: A Therapeutic Perspective.Int J Mol Sci. 2023 Sep 13;24(18):14044. doi: 10.3390/ijms241814044. Int J Mol Sci. 2023. PMID: 37762346 Free PMC article. Review.
-
Impact of nanoparticles on amyloid β-induced Alzheimer's disease, tuberculosis, leprosy and cancer: a systematic review.Biosci Rep. 2023 Feb 27;43(2):BSR20220324. doi: 10.1042/BSR20220324. Biosci Rep. 2023. PMID: 36630532 Free PMC article.
-
Advanced nanomaterials for modulating Alzheimer's related amyloid aggregation.Nanoscale Adv. 2022 Nov 21;5(1):46-80. doi: 10.1039/d2na00625a. eCollection 2022 Dec 20. Nanoscale Adv. 2022. PMID: 36605800 Free PMC article. Review.
-
Polyoxometalate-peptide hybrid materials: from structure-property relationships to applications.Chem Sci. 2022 Nov 16;14(1):10-28. doi: 10.1039/d2sc05105b. eCollection 2022 Dec 21. Chem Sci. 2022. PMID: 36605748 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
